Stan Berenshteyn
Stock Analyst at Wells Fargo
(1.12)
# 3,435
Out of 4,793 analysts
63
Total ratings
43.33%
Success rate
-11.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GDRX GoodRx Holdings | Maintains: Overweight | $9 → $8 | $4.12 | +94.17% | 7 | Feb 28, 2025 | |
| HQY HealthEquity | Maintains: Overweight | $110 → $125 | $78.80 | +58.63% | 9 | Feb 26, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $43 → $55 | $51.24 | +7.34% | 10 | Feb 7, 2025 | |
| HCAT Health Catalyst | Maintains: Overweight | $13 → $10 | $4.01 | +149.38% | 5 | Jan 21, 2025 | |
| OMCL Omnicell | Maintains: Equal-Weight | $49 → $40 | $32.69 | +22.36% | 12 | Jan 13, 2025 | |
| AMWL American Well | Upgrades: Overweight | $15 | $6.59 | +127.62% | 3 | Jan 13, 2025 | |
| VEEV Veeva Systems | Maintains: Overweight | $275 → $285 | $213.68 | +33.38% | 5 | Dec 6, 2024 | |
| ACCD Accolade | Maintains: Equal-Weight | $7 → $6 | $7.03 | -14.65% | 10 | Oct 11, 2024 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $28 → $23 | $7.29 | +215.50% | 2 | Mar 6, 2023 |
GoodRx Holdings
Feb 28, 2025
Maintains: Overweight
Price Target: $9 → $8
Current: $4.12
Upside: +94.17%
HealthEquity
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $78.80
Upside: +58.63%
Doximity
Feb 7, 2025
Maintains: Equal-Weight
Price Target: $43 → $55
Current: $51.24
Upside: +7.34%
Health Catalyst
Jan 21, 2025
Maintains: Overweight
Price Target: $13 → $10
Current: $4.01
Upside: +149.38%
Omnicell
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $49 → $40
Current: $32.69
Upside: +22.36%
American Well
Jan 13, 2025
Upgrades: Overweight
Price Target: $15
Current: $6.59
Upside: +127.62%
Veeva Systems
Dec 6, 2024
Maintains: Overweight
Price Target: $275 → $285
Current: $213.68
Upside: +33.38%
Accolade
Oct 11, 2024
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $7.03
Upside: -14.65%
Teladoc Health
Mar 6, 2023
Maintains: Equal-Weight
Price Target: $28 → $23
Current: $7.29
Upside: +215.50%